Prognostic factors for patients with liver metastases from breast cancer

Eichbaum, Michael; Kaltwasser, Margarete; Brückner, Thomas; Rossi, Thomas M.; Schneeweiß, Andreas; Sohn, Christof

doi:10.1007/s10549-005-9039-1

Cited by 60 publications

(44 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although toxicity data in patients aged $65 years have not been reported for the MPACT study to date, a separate analysis of dosing in the study revealed that the percentage of dose reductions in the nabpaclitaxel plus gemcitabine arm was similar regardless of age ($65 vs. ,65 years) [11]. Taken together, the findings of this analysis are particularly relevant considering that patients with these characteristics (e.g., advanced age, poor performance status, presence of liver metastasis, or more than three metastatic sites) tend to have especially poor survival outcomes [12][13][14][15].…”

Section: Wwwtheoncologistcom ©Alphamed Press 2015mentioning

confidence: 98%

Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

et al. 2015

View full text Add to dashboard Cite

Background. nab-Paclitaxel in combination with gemcitabine has emerged as a new treatment option for patients with metastatic pancreatic cancer (MPC), based on superiority over gemcitabine demonstrated in the phase III MPACT trial. Previously, Karnofsky performance status (KPS) score and the presence of liver metastases were shown to be predictive of survival with nab-paclitaxel plus gemcitabine treatment. This analysis sought to further explore the relationship between clinical characteristics and survival in the MPACT trial and to identify potential predictors of overall survival and progression-free survival in patients with MPC. Materials and Methods. Cox regression models adjusted for stratification factors and a stepwise multivariate analysis of prespecified baseline prognostic factors were performed. Results. Treatment effect was significantly associated with survival, with a similar magnitude of reduction in risk of

show abstract

Section: Wwwtheoncologistcom ©Alphamed Press 2015mentioning

confidence: 98%

Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Gastric cancers also commonly metastasize to the liver (7). Circulating cells from other primary malignancies, such as melanoma, breast or neuroendocrine tumors (8)(9)(10), also adhere, establish and develop in the liver, giving rise to metastases, although this is less common.…”

Section: Introductionmentioning

confidence: 99%

Role of liver ICAM-1 in metastasis

2017

View full text Add to dashboard Cite

Abstract. Intercellular adhesion molecule (ICAM)-1, is a transmembrane glycoprotein of the immunoglobulin (Ig)-like superfamily, consisting of five extracellular Ig-like domains, a transmembrane domain and a short cytoplasmic tail. ICAM-1 is expressed in various cell types, including endothelial cells and leukocytes, and is involved in several physiological processes. Furthermore, it has additionally been reported to be expressed in various cancer cells, including melanoma, colorectal cancer and lymphoma. The majority of studies to date have focused on the expression of the ICAM-1 on the surface of tumor cells, without research into ICAM-1 expression at sites of metastasis. Cancer cells frequently metastasize to the liver, due to its unique physiology and specialized liver sinusoid capillary network. Liver sinusoidal endothelial cells constitutively express ICAM-1, which is upregulated under inflammatory conditions. Furthermore, liver ICAM-1 may be important during the development of liver metastasis. Therefore, it is necessary to improve the understanding of the mechanisms mediated by this adhesion molecule in order to develop host-directed anticancer therapies.

show abstract

“…Breast cancer cells preferentially metastasize to specific organs and tissues, with the liver representing the third most frequent site following bone and lung (Clark et al, 1987;Insa et al, 1999). Breast cancer patients with liver metastases display a poor prognosis, with median survival times between 14 and 20 months and 5-year survival rates that reach only 5.5-8.5% (Pentheroudakis et al, 2005;Eichbaum et al, 2006). However, little is known about the molecular mechanisms governing the spread and growth of breast cancer cells in the liver.…”

Section: Introductionmentioning

confidence: 99%

Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes

et al. 2010

View full text Add to dashboard Cite

The liver represents the third most frequent site of metastasis in patients with breast cancer. We performed in vivo selection using 4T1 breast cancer cells to identify genes associated with the liver metastatic phenotype. Coincident with the loss of numerous tight-junctional proteins, we observe claudin-2 overexpression, specifically in liver-aggressive breast cancer cells. We further demonstrate that claudin-2 is both necessary and sufficient for the ability of 4T1 breast cancer cells to colonize and grow in the liver. The liver-aggressive breast cancer cells display a claudin-2-mediated increase in their ability to adhere to extracellular matrix (ECM) components, such as fibronectin and type IV collagen. Claudin-2 facilitates these cell/matrix interactions by increasing the cell surface expression of a 2 b 1 -and a 5 b 1 -integrin complexes in breast cancer cells. Indeed, claudin-2-mediated adhesion to fibronectin and type IV collagen can be blocked with neutralizing antibodies that target a 5 b 1 and a 2 b 1 complexes, respectively. Immunohistochemical analyses reveal that claudin-2, although weakly expressed in primary human breast cancers, is readily detected in all liver metastasis samples examined to date. Together, these results uncover novel roles for claudin-2 in promoting breast cancer adhesion to the ECM and define its importance during breast cancer metastasis to the liver.

show abstract

Prognostic factors for patients with liver metastases from breast cancer

Abstract: Consideration of prognostic implications of the described parameters may help to find the most appropriate treatment for patients with liver metastases from breast cancer. The possibility of local therapeutic interventions should be considered in a defined subgroup.

Cited by 60 publications

References 29 publications

Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

Role of liver ICAM-1 in metastasis

Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes

Contact Info

Product

Resources

About